Details
ToMORROW gives dairy producers time-tested, broad-spectrum control against the harmful organisms that cause mastitis in dry cows.
-
ToMORROW has been an effective prolonged therapy treatment for more than 25 years, and studies have shown no change in the development of bacterial resistance.1,2
-
ToMORROW has been shown by extensive clinical studies to be efficacious in the treatment of mastitis in dry cows when caused by Streptococcus agalactiae and Staphylococcus aureus including penicillin-resistant strains.
-
ToMORROW is formulated with cephapirin benzathine to provide broad spectrum and long-acting therapy that dry cows need.
Features & Benefits
TOP REASONS TO USE ToMORROW® (cephapirin benzathine)
-
Shorter milk withhold.
72 hours after calving versus 96 hours for QUARTERMASTER means you can put your cows back into production sooner after calving.
-
Shorter slaughter withhold.
42 days after last infusion with ToMORROW treatment compared to 60 days for QUARTERMASTER allows you to move 18 days faster.
-
Targets the bacteria most common at dry-off.
ToMORROW treatment effectively controls Gram-positive organisms, which represent 94% of infections that occur during dry-off.1
-
Less expensive, equally effective.
Producers and vets can save an average of 35% per cow when treating with ToMORROW vs. SPECTRAMAST DC.3
-
Increases convenience and reduces the risk of new infections.
The Opti-Sert® tip reduces new mastitis infections by up to 50%4 and makes partial insertion much easier.
Dosage & Administration
Presentations
Partial insertion reduces new infections
-
With the Opti-Sert® applicator tip, partial insertion reduces the incidence of new infections during the dry period.4
-
Studies have shown that when infusing into the udder at a depth of 2 to 3 millimeters, as opposed to 5 or more millimeters, new intramammary infections can be reduced by as much as 50 percent.4
Dosage Information
